FDA Greenlights AbbVie And Genmab's EPKINLY Combo For Relapsed Or Refractory Follicular Lymphoma

AbbVie said the FDA approved EPKINLY, a subcutaneously administered CD20xCD3 T‑cell engaging bispecific, in combination with rituximab and lenalidomide (R2) for adults with relapsed or refractory follicular lymphoma, offering a fixed‑duration, chemotherapy‑free outpatient regimen. Approval was based on the phase 3 EPCORE FL‑1 trial which showed a 79% reduction in risk of progression or death versus R2 alone, overall response rates of 89% versus 74%, complete responses of 74% versus 43%, and median progression‑free survival not reached; safety was described as generally manageable. AbbVie is co‑developing and commercializing EPKINLY with Genmab under a 2020 agreement (AbbVie leads ex‑U.S./Japan commercialization; Genmab records U.S./Japan net sales and tiered royalties elsewhere), and detailed trial data will be presented at ASH in December 2025. AbbVie shares have traded in a $164.39–$244.81 range over the past year and closed most recently at $233.87, down 0.06%.

Analysis

AbbVie announced FDA approval of EPKINLY in combination with rituximab and lenalidomide (R2) for adults with relapsed or refractory follicular lymphoma; EPKINLY is a subcutaneously administered CD20xCD3 T-cell engaging bispecific offered as a fixed-duration, chemotherapy-free outpatient regimen. Approval rested on phase 3 EPCORE FL-1 results showing a 79% reduction in risk of progression or death versus R2 alone, overall response rate (ORR) of 89% versus 74%, complete response (CR) rate of 74% versus 43%, and median progression-free survival not reached, with safety described as generally manageable. Under a 2020 collaboration with Genmab, AbbVie and Genmab will share U.S./Japan commercial responsibilities while AbbVie leads commercialization elsewhere; Genmab will record U.S./Japan net sales and receive tiered royalties in other markets, which meaningfully affects where revenue accrues. Market reaction was muted—ABBV closed at $233.87, down 0.06%, trading in a $164.39–$244.81 range over the past year—while the full EPCORE FL-1 dataset due at ASH December 2025 and real-world uptake, reimbursement and post‑marketing safety are primary near-term catalysts and risks.

Key Decisions for Investors

• Investors should consider increasing exposure to ABBV given FDA approval and strong pivotal efficacy metrics, but size allocations prudently given the stock is trading near its 52-week high
• Monitor the ASH December 2025 presentation and initial post-approval safety and sales data as primary catalysts to validate durability and commercial uptake before making larger commitments
• Track early commercialization metrics and the AbbVie–Genmab revenue split closely since Genmab will report U.S./Japan net sales while AbbVie leads other markets, which will influence reported top-line and regional margin profiles
• If near-term upside appears limited relative to current share price, execute phased entries or use short-term hedges until reimbursement clarity and launch sales trends materialize